Taysha Gene Therapies Inc
NASDAQ:TSHA

Watchlist Manager
Taysha Gene Therapies Inc Logo
Taysha Gene Therapies Inc
NASDAQ:TSHA
Watchlist
Price: 1.7 USD -7.1% Market Closed
Market Cap: 348.5m USD

P/OCF
Price to OCF

-4.3
Current
-3.8
Median
19.8
Industry
Lower than median
Lower than industry value

Price to Operating Cash Flow (P/OCF) ratio is a valuation multiple that measures the value of a company’s market capitalization relative to the operating cash flow it generates. Some analysts prefer P/OCF over P/E since earnings can be more easily manipulated than cash flows.

P/OCF
-4.3
=
Market Cap
348.4m USD
/
Operating Cash Flow
-81.2m USD
 
US
Taysha Gene Therapies Inc
NASDAQ:TSHA
Average P/OCF: 17.9
Negative Multiple: -4.3
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -229 667.2
US
Abbvie Inc
NYSE:ABBV
19.9
US
Amgen Inc
NASDAQ:AMGN
14.7
US
Gilead Sciences Inc
NASDAQ:GILD
12.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -266.1
US
E
Epizyme Inc
F:EPE
Negative Multiple: -489.8
AU
CSL Ltd
ASX:CSL
26.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -79.1
NL
argenx SE
XBRU:ARGX
Negative Multiple: -142.1

P/OCF Forward Multiples

Forward P/OCF multiple is a version of the P/OCF ratio that uses forecasted operating cash flow for the P/OCF calculation. 1-Year, 2-Years, and 3-Years forwards use operating cash flow forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/OCF
N/A
2-Years Forward
P/OCF
N/A
3-Years Forward
P/OCF
N/A